Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PanRORα

Financiado

Cerrado

Acute pancreatitis therapy by ROR activation and FGF21 expression

Pancreatitis in humPancreatitis in humans is a cause of significant morbidity and mortality. Acute pancreatitis events have increased worldwide over the last 20 years at an average annual percent change of 3% and the economic burd... ver más

30/04/2026

Líder desconocido

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto Líder desconocido

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-10-21

ERC-2024-POC: ERC PROOF OF CONCEPT GRANTS Objective:ObjectivesThe ERC Proof of Concept Grants aim at facilitating exploration of the commercia...

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

THE HEBREW UNIVERSITY OF JER...

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 18 meses Fecha Inicio: 2024-10-21
Fecha Fin: 2026-04-30

Líder del proyecto Líder desconocido

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Pancreatitis in humPancreatitis in humans is a cause of significant morbidity and mortality. Acute pancreatitis events have increased worldwide over the last 20 years at an average annual percent change of 3% and the economic burden is growing (1). Treatments for pancreatitis are currently limited. The overall mortality rate in acute severe pancreatitis is 10-15%. Thus, a specific treatment for pancreatitis is of great need. Recent reports suggest that FGF21 can ameliorate acute pancreatitis in mice. FGF21 is a protein which belongs to the fibroblast growth factor family and is predominantly produced and secreted by the liver. FGF21 is positively regulated by the RORα transcription factor. I will assess whether a RORα agonist that we identified by screening compounds that act against Non-Alcoholic Steatohepatitis (NASH) in mice, and which we found to increase FGF21 expression, can be used to treat acute pancreatitis (2). In addition, we will also investigate whether increased FGF21 expression can be used to prevent pancreatitis triggered by Endoscopic Retrograde CholangioPancreatography (ERCP). We established the Caerulein and alcohol induced pancreatitis models. In the Caerulein model we show [unpublished and patented (US Pending Patent 11,865,090)] significant therapeutic effects of a small compound that activates RORα. In this PoC, we intend to explore new compounds of the same family with better efficacy on FGF21 in vivo, and improve the treatment for acute pancreatitis. This study will establish FGF21 as a prognostic biomarker for acute pancreatitis in humans, by plasma ELISA and circulating free DNA. This PoC project has the potential to achieve a breakthrough therapeutic treatment for acute pancreatitis; one that is commercially viable, effective, avoids an immune response and has the benefits of a natural delivery, a natural chemical composition of FGF21, lower cost, higher availability, simple storage and overcomes the short half-life of synthetic proteins.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores